Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Cervical cytology and human papillomavirus among asymptomatic healthy volunteers in Vientiane, Lao PDR

Authors: Reika Takamatsu, Viengvansay Nabandith, Vatsana Pholsena, Phouthasone Mounthisone, Katsu Nakasone, Kentarou Ohtake, Naoki Yoshimi

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Cervical cancer is the most common cancer in women living in Vientiane, Lao People’s Democratic Republic (PDR). This study examines cervical cytology using a liquid-based cytology (LBC) method and reports the presence of high-risk (HR) human papillomavirus (HPV).

Methods

We collected cervical samples from 1475 asymptomatic and healthy volunteers from six hospitals in Lao PDR. A total of 1422 volunteers (mean age 39.1 ± 6.4 years, range 30-54 years) were included in the final analysis. We performed HPV typing using the polymerase chain reaction technique to detect HR-HPV samples with abnormal cytology.

Results

The overall rates of abnormal cytology and HR-HPV–positive in the samples were 9.3% (132/1422) and 47.7% (63/132), respectively. The samples with abnormal cytology included 13 high-grade squamous intraepithelial lesions and one squamous cell carcinoma case. The results showed that the most common type of HPV was HPV16 (20.5%) followed by HPV58 (9.1%).

Conclusions

Healthy women in Vientiane, the capital of Lao PDR, have high rates of abnormal cervical cytology and are likely to be HR-HPV-positive. A system for detection and prevention of cervical cancer in these women should be developed in the near future.
Appendix
Available only for authorised users
Literature
1.
International Agency for Research on Cancer, GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://​globocan.​iarc.​fr. Accessed 1 June 2016.
2.
Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Int. 2002;94:1469–83.CrossRef
3.
Chamberlain J. Reasons that some screening programmes fail to control cervical cancer. IARC Sci Publ. 1986;76:161–8.
4.
Denny L. Cytological screening for cervical cancer prevention. Best Pract Res Clin Obstet Gynecol. 2012;26:189–96.CrossRef
5.
6.
Brown B, Davtyan M, Galea J, et al. The role of human papillomavirus in human immunodeficiency virus acquisition in men who have sex with men, a review of the literature. Viruses. 2012;4:3851–8.CrossRefPubMedPubMedCentral
7.
Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003;348:489–90.CrossRefPubMed
8.
zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology. 2009;384:260-5.
9.
10.
Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78–88.CrossRefPubMed
11.
Pileggi C, Flotta D, Bianco A, Nobile CG, Pavia M. Is HPV DNA testing specificity comparable to that of cytological testing in primary cervical cancer screening? Results of a meta-analysis of randomized controlled trials. Int J Cancer. 2014;135:166–77.CrossRefPubMed
12.
Phongsavan K, Gustavsson I, Marions L, et al. Detection of human papillomavirus among women in Laos: feasibility of using filter paper card and prevalence of high-risk types. Int J Gynecol Cancer. 2012;22:1398–406.CrossRefPubMed
13.
Nabandith V, Pholsena V, Mounthisone P, et al. First trial of cervical cytology in healthy women of urban Laos using a self-sampling instrument. Asian Pacific J Cancer Prev. 2012;13:4665–7.CrossRef
14.
Kuroshima Y, Ohtake K, Handou K, et al. Investigation using a self-scraping instrument for uterine cervical cancer screening in Laos. J Jpn Soc Clin Cytol. 2014;53:55–9. (in Japanese)CrossRef
15.
Okayama K, Okodo M, Fujii M, et al. Improved accuracy of cytodiagnosis using the Kato self-collection device, the usefulness of smear preparation in liquid-based cytology methods. Asian Pac J Cancer Prev. 2012;13:4521–4.CrossRefPubMed
16.
Sichanh C, Quet F, Chanthavilay P, et al. Knowledge, awareness and attitudes about cervical cancer among women attending or not an HIV treatment center in Lao PDR. BMC Cancer. 2014;14:161.CrossRefPubMedPubMedCentral
17.
Beerman H, van Dorst EBL, Kuenen-Boumeester V, et al. Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program. Gynecol Oncol. 2009;112:572–6.CrossRefPubMed
18.
Kituncharoen S, Tantbirojn P, Niruthisard S. Comparison of unsatisfactory rates and detection of abnormal cervical cytology between conventional Papanicolaou smear and liquid-based cytology (sure path®). Asian Pac J Cancer Prev. 2015;16:8491–4.CrossRefPubMed
19.
Kuroshima Y, Ohtake Akamine K, et al. Effectiveness of LBC introduction to municipality cervical cancer screening of the Chubu District in the main island of Okinawa. J Jpn Soc Clin Cytol. 2016;55:137–41. (in Japanese)CrossRef
20.
Kantathavorn N, Mahidol C, Sritana N, et al. Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs. Infect Agent Cancer. 2015;10:7.CrossRefPubMedPubMedCentral
21.
LT V, Bui D, Le HTT. Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign. BMC Cancer. 2013;13:1.CrossRef
22.
Mu-Mu-Shwe HT, Okada S, et al. Prevalence of high-risk human papillomavirus (HR-HPV) infection among women with normal and abnormal cervical cytology in Myanmar. Acta Med Okayama. 2014;68:79–87.PubMed
23.
Cibas ES, Zou KH, Crum CP, et al. Using the rate of positive high-risk HPV test results for ASC-US together with the ASC-US/SIL ratio in evaluating the performance of cytopathologists. Am J Clin Pathol. 2008;129:97–101.CrossRefPubMed
24.
de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology, a meta-analyses. Lancet Infect Dis. 2007;7:453–9.CrossRefPubMed
25.
Bruni L, Diaz M, Castellsague X, et al. Cervical human papillomavirus prevalence in 5 continents, meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202:1789–99.CrossRefPubMed
26.
Goldie SJ, O'Shea M, Diaz M, et al. Benefits, cost requirements and cost-effectiveness of the HPV16, 18 vaccine for cervical cancer prevention in developing countries: policy implications. Repro Health Matters. 2008;16:86–96.CrossRef
27.
Fontenot HB, Domush V, Zimet GD. Parental attitudes and beliefs regarding the nine-valent human papillomavirus vaccine. J Adolesc Health. 2015;57:595–600.CrossRefPubMed
28.
Jeronimo J, Bansil P, Lim J, et al. A multicountry evaluation of care HPV testing, visual inspection with acetic acid, and Papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer. 2014;24:576–85.CrossRefPubMedPubMedCentral
29.
Yoshida T, Nishijima Y, Hando K, et al. Primary study on providing a basic system for uterine cervical screening in a developing country: analysis of acceptability of self-sampling in Lao PDR. Asian Pac J Cancer Prev. 2013;14:3029–35.CrossRefPubMed
Metadata
Title
Cervical cytology and human papillomavirus among asymptomatic healthy volunteers in Vientiane, Lao PDR
Authors
Reika Takamatsu
Viengvansay Nabandith
Vatsana Pholsena
Phouthasone Mounthisone
Katsu Nakasone
Kentarou Ohtake
Naoki Yoshimi
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3900-6

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis

Research article

YRNA expression predicts survival in bladder cancer patients

Research article

Do pre-diagnosis primary care consultation patterns explain deprivation-specific differences in net survival among women with breast cancer? An examination of individually-linked data from the UK West Midlands cancer registry, national screening programme and Clinical Practice Research Datalink

Research article

Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature

Research article

Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73

Study protocol

Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits